SVB Leerink Downgrades Pacira Pharmaceuticals (PCRX) to Market Perform
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $23.82 -2.3%
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 6
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 6
Join SI Premium – FREE
SVB Leerink analyst Ami Fadia downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Outperform to Market Perform with a price target of $75.00.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $73.34 yesterday.
You May Also Be Interested In
- Oppenheimer Downgrades Legend Biotech Corp. (LEGN) to Perform, 'CEO/Partnership/Competition Overhangs to Cap Upside'
- BofA Securities Downgrades Bending Spoons (BSP) to Underperform
- Northcoast Downgrades MarineMax (HZO) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
